Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development
Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development gathers diverse experts to present state of the art guidance and application of histopathology in drug development settings ranging from discovery research to human clinical
- PDF / 9,846,615 Bytes
- 384 Pages / 504.63 x 737.01 pts Page_size
- 48 Downloads / 188 Views
Steven J. Potts David A. Eberhard Keith A. Wharton, Jr. Editors
Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development
METHODS AND
IN
PHARMACOLOGY
TOXICOLOGY
Series Editor Y. James Kang Department of Medicine University of Louisville School of Medicine Prospect, Kentucky, USA
For further volumes: http://www.springer.com/series/7653
Molecular Histopathology and Tissue Biomarkers in Drug and Diagnostic Development Edited by
Steven J. Potts Flagship Biosciences, LLC, Westminster, CO, USA
David A. Eberhard University of North Carolina, Chapel Hill, NC, USA
Keith A. Wharton, Jr. Novartis Institutes for BioMedical Research, Cambridge, MA, USA
Editors Steven J. Potts Flagship Biosciences, LLC Westminster, CO, USA
David A. Eberhard University of North Carolina Chapel Hill, NC, USA
Keith A. Wharton, Jr. Novartis Institutes for BioMedical Research Cambridge, MA, USA
ISSN 1557-2153 ISSN 1940-6053 (electronic) Methods in Pharmacology and Toxicology ISBN 978-1-4939-2680-0 ISBN 978-1-4939-2681-7 (eBook) DOI 10.1007/978-1-4939-2681-7 Library of Congress Control Number: 2015939268 Springer New York Heidelberg Dordrecht London # Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Humana Press is a brand of Springer Springer Science+Business Media LLC New York is part of Springer Science+Business Media (www.springer.com)
Dedication
Chris Callahan, M.D., Ph.D. This book is dedicated to the memory of our dear friend and esteemed colleague, Chris Callahan, M.D., Ph.D., who suffered an untimely death from a progressive brain tumor in 2011. Already recognized as a leader early in his career, Chris held the position of Scientist and Investigative Pathologist at Genentech/Roche at the time of his passing at the young age of 46. Chris’s professional contributions pervade this book’s themes of molecular histopathology and tissue-based biomarkers, and several of its contributors trained
Data Loading...
